{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:43:07Z","timestamp":1793367787377,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.semarthrit.2018.04.003","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T13:18:07Z","timestamp":1523971087000},"page":"618-625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Biologics in SAPHO syndrome: A systematic review"],"prefix":"10.1016","volume":"48","author":[{"given":"Dimitrios","family":"Daoussis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Konstantopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9149-1586","authenticated-orcid":false,"given":"Pantelis","family":"Kraniotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-3314","authenticated-orcid":false,"given":"Lazaros","family":"Sakkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatis-Nick","family":"Liossis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2018.04.003_bib1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.semarthrit.2012.05.006","article-title":"The SAPHO syndrome","volume":"42","author":"Nguyen","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib2","first-page":"187","article-title":"Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases","volume":"54","author":"Chamot","year":"1987","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11832-014-0627-7","article-title":"SAPHO syndrome: a review","volume":"9","author":"Rukavina","year":"2015","journal-title":"J Child Orthop"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jbspin.2006.06.006","article-title":"Valuable lessons from SAPHO syndrome","volume":"74","author":"Hayem","year":"2007","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.berh.2011.01.017","article-title":"The SAPHO syndrome\u2014are microbes involved?","volume":"25","author":"Assmann","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.semarthrit.2016.04.004","article-title":"SAPHO: treatment options including bisphosphonates","volume":"46","author":"Zwaenepoel","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11926-016-0583-y","article-title":"SAPHO syndrome: current developments and approaches to clinical treatment","volume":"18","author":"Firinu","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/rheumatology\/kei221","article-title":"In SAPHO syndrome anti-TNF-\u03b1 therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations","volume":"45","author":"Massara","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.crohns.2012.08.007","article-title":"Induction or exacerbation of psoriatic lesions during anti-TNF-\u03b1 therapy for inflammatory bowel disease: a systematic literature review based on 222 cases","volume":"7","author":"Denadai","year":"2013","journal-title":"J Crohn\u2019s Colitis"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib10","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3899\/jrheum.091086","article-title":"Tumor necrosis factor\u2014blockers in SAPHO syndrome","volume":"37","author":"Ben Abdelghani","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib11","first-page":"444","article-title":"Biologics for rare inflammatory diseases: TNF blockade in the SA PHO syndrome","volume":"70","author":"Burgemeister","year":"2012","journal-title":"Neth J Med"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/120347540400800202","article-title":"A review of the use of infliximab to manage cutaneous dermatoses","volume":"8","author":"Gupta","year":"2004","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/ard.61.4.375","article-title":"Successful treatment of SAPHO syndrome with infliximab: report of two cases","volume":"61","author":"Olivieri","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.semarthrit.2007.08.004","article-title":"Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature","volume":"37","author":"Moll","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00296-012-2606-y","article-title":"The lobster sign in SAPHO syndrome: unusually extensive osteitis of the anterior chest wall partially responsive to infliximab","volume":"34","author":"Ani\u0107","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib16","first-page":"185","article-title":"SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate","volume":"69","author":"De Souza","year":"2011","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.10.2008.1145","article-title":"Response to infliximab in SAPHO syndrome","volume":"2009","author":"Fruehauf","year":"2009","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib18","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.jaad.2004.09.006","article-title":"Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab","volume":"52","author":"Iqbal","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10067-007-0767-y","article-title":"Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism","volume":"27","author":"Sabugo","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.reuma.2015.11.016","article-title":"SAPHO syndrome presenting as an osteolytic lesion of the neck","author":"Mateo","year":"2017","journal-title":"Reumatol Cl\u00ednica"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-007161","article-title":"Successful treatment of resistant SAPHO syndrome with anti-TNF therapy","author":"Hampton","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib22","first-page":"62","article-title":"Etanercept in the treatment of refractory SAPHO syndrome","volume":"5","author":"Zhang","year":"2016","journal-title":"Am J Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib23","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/art.10539","article-title":"Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome","volume":"46","author":"Wagner","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5152\/eurjrheumatol.2014.037","article-title":"Etanercept in the treatment of SAPHO syndrome: which place?","volume":"1","author":"Abourazzak","year":"2014","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib25","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s00296-011-1916-9","article-title":"Successful treatment of SAPHO syndrome with severe spinal disorder using entercept: a case study","volume":"32","author":"Zhang","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib26","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3899\/jrheum.091086","article-title":"Tumor necrosis factor-\u03b1 blockers in SAPHO syndrome","volume":"37","author":"Abdelghani","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib27","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2340\/00015555-0895","article-title":"SAPHO syndrome with unusual cutaneous manifestations treated successfully with etanercept","volume":"90","author":"Bastida","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib28","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jfma.2013.10.001","article-title":"SAPHO syndrome associated with acne conglobata successfully treated with etanercept","volume":"114","author":"Su","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib29","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.jcms.2014.09.004","article-title":"Diffuse sclerosing osteomyelitis (DSO) of the mandible in SAPHO syndrome: a novel approach with anti-TNF therapy. Systematic review","volume":"42","author":"Mar\u00ed","year":"2014","journal-title":"J Cranio-Maxillofacial Surg"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib30","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1111\/ijd.12675","article-title":"Etanercept in the treatment of SAPHO syndrome","volume":"54","author":"S\u00e1ez-Mart\u00edn","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib31","doi-asserted-by":"crossref","unstructured":"Cianci F, Zoli A, Gremese E, Ferraccioli G. Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment. \u3008doi:10.1007\/s10067-017-3751-1\u3009","DOI":"10.1007\/s10067-017-3751-1"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.11.2011.5197","article-title":"The dark side of SAPHO syndrome","volume":"2011","author":"Henriques","year":"2011","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib33","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.joen.2015.04.005","article-title":"A case of SAPHO syndrome with endodontic implications and treatment with biologic drugs","volume":"41","author":"Cotti","year":"2015","journal-title":"J Endod"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib34","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10067-010-1476-5","article-title":"Successful treatment of SAPHO syndrome with adalimumab: a case report","volume":"29","author":"Castellv\u00ed","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2340\/00015555-0822","article-title":"Adalimumab treatment for SAPHO syndrome","volume":"90","author":"Arias-Santiago","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/11593250-000000000-00000","article-title":"Long-term treatment of severe SAPHO syndrome with adalimumab","volume":"13","author":"Garcovich","year":"2012","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ijd.13740","article-title":"SAPHO syndrome associated with hidradenitis suppurativa and pyoderma gangrenosum successfully treated with adalimumab and methotrexate: a case report and review of the literature","volume":"57","author":"Vekic","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib38","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00296-015-3263-8","article-title":"Successful treatment of a patient with SAPHO syndrome with certolizumab pegol","volume":"35","author":"Kamata","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib39","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/annrheumdis-2011-200743","article-title":"Anakinra treatment of SAPHO syndrome: short-term results of an open study","volume":"71","author":"Wendling","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib40","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/rheumatology\/keq074","article-title":"Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra","volume":"49","author":"Colina","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib41","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00296-011-2020-x","article-title":"Adult-onset Still's disease and chronic recurrent multifocal osteomyelitis: a hitherto undescribed manifestation of autoinflammation","volume":"32","author":"Rech","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib42","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/rheumatology\/keq122","article-title":"Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood","volume":"49","author":"Eleftheriou","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2017.05.016","article-title":"IL-23\/Th17 targeted therapies in SAPHO syndrome. A case series","author":"Wendling","year":"2017","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib44","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2174\/1871528113666140520100402","article-title":"Biological treatments for SAPHO syndrome: an update","volume":"13","author":"Firinu","year":"2014","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib45","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1684\/ejd.2016.2854","article-title":"Interstitial granulomatous dermatitis occurring in a patient with SAPHO syndrome one month after starting leflunomide, and subsequently disappearing with ustekinumab","volume":"26","author":"Cornillier","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib46","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/annrheumdis-2017-eular.4360","article-title":"AB0039\u2005Reduction of TH17+ lymphocytes in part of sapho patients on treatment with secukinumab","volume":"76","author":"Assmann","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib47","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/1756-185X.12525","article-title":"Development of aseptic subcutaneous abscess after tocilizumab therapy in a patient with SAPHO syndrome complicated by amyloid A amyloidosis","volume":"18","author":"Fujita","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib48","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.2169\/internalmedicine.8473-16","article-title":"Adult-onset chronic recurrent multifocal osteomyelitis with high intensity of muscles detected by magnetic resonance imaging, successfully controlled with tocilizumab","volume":"56","author":"Sato","year":"2017","journal-title":"Intern Med"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib49","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.rdc.2013.05.002","article-title":"Autoinflammatory bone diseases","volume":"39","author":"Stern","year":"2013","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib50","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-med-061512-150641","article-title":"IL-1 blockade in autoinflammatory syndromes","volume":"65","author":"Jesus","year":"2014","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib52","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/08916934.2014.906582","article-title":"T H 17 cells are increased in the peripheral blood of patients with SAPHO syndrome","volume":"47","author":"Firinu","year":"2014","journal-title":"Autoimmunity"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib53","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","article-title":"An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist","volume":"360","author":"Aksentijevich","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib54","unstructured":"Miossec P. Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice. \u3008doi:10.1136\/\u3009"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib55","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s10067-015-2961-7","article-title":"Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis","volume":"34","author":"Raychaudhuri","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13075-017-1249-5","article-title":"Mechanistic rationales for targeting interleukin-17A in spondyloarthritis","volume":"19","author":"Raychaudhuri","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/jid.2013.400","article-title":"IL-17: a key player in the P. acnes inflammatory cascade?","volume":"134","author":"Thiboutot","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib58","doi-asserted-by":"crossref","first-page":"e105238","DOI":"10.1371\/journal.pone.0105238","article-title":"IL-17\/Th17 pathway is activated in acne lesions","volume":"9","author":"Kelh\u00e4l\u00e4","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib59","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/jid.2013.334","article-title":"Propionibacterium acnes induces an IL-17 response in acne vulgaris that is regulated by vitamin A and vitamin D","volume":"134","author":"Agak","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib60","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/PTT.S98954","article-title":"Pustular psoriasis: pathophysiology and current treatment perspectives","volume":"6","author":"Mansouri","year":"2016","journal-title":"Psoriasis Targets Ther"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib61","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1600-0625.2011.01325.x","article-title":"Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum","volume":"20","author":"Murakami","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jdermsci.2016.09.019","article-title":"Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway","volume":"85","author":"Bissonnette","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib63","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/1346-8138.13306","article-title":"Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study","volume":"43","author":"Imafuku","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib64","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","article-title":"Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial","volume":"76","author":"Gottlieb","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib65","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/ar2642","article-title":"Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis","volume":"11","author":"Lories","year":"2009","journal-title":"Arthritis ResTher"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.04.003_bib66","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.semarthrit.2008.10.008","article-title":"Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis","volume":"39","author":"Daoussis","year":"2010","journal-title":"Semin Rheum"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib67","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib68","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bone.2016.01.010","article-title":"Proinflammatory T cells and IL-17 stimulate osteoblast differentiation","volume":"84","author":"Croes","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib69","doi-asserted-by":"crossref","first-page":"10928","DOI":"10.1038\/ncomms10928","article-title":"IL-17-producing \u03b3\u03b4 T cells enhance bone regeneration","volume":"7","author":"Ono","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib70","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fimmu.2015.00151","article-title":"Differential effects of IL-17A and TNF-\u03b1 on osteoblastic differentiation of isolated synoviocytes and on bone explants from arthritis patients","volume":"6","author":"Osta","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib71","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3389\/fimmu.2014.00425","article-title":"Effects of interleukin-17A on osteogenic differentiation of isolated human mesenchymal stem cells","volume":"5","author":"Osta","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib72","unstructured":"van Tok M, van Duivenvoorde L, Kramer I, Ingold P, Knaup V, Taurog J, et al. Anti-IL-17A, but not anti-TNF, can halt pathological new bone formation in experimental spondyloarthritis\u2014ACR meeting abstracts. Arthritis Rheumatol. 2016; 68 (suppl 10). http:\/\/acrabstracts.org\/abstract\/anti-il-17a-but-not-anti-tnf-can-halt-pathological-new-bone-formation-in-experimental-spondyloarthritis\/. Accessed 10 Nov 2017."},{"key":"10.1016\/j.semarthrit.2018.04.003_bib73","doi-asserted-by":"crossref","unstructured":"van Tok M, van Duivenvoorde L, Kramer I, Ingold P, Taurog J, Kolbinger F. BD Anti-IL-17A treatment blocks inflammation, destruction and new bone formation in experimental spondyloarthritis in HLA-B27 transgenic rats\u2014ACR meeting abstracts. In: Arthritis Rheumatol. 2015; 67 (suppl 10). http:\/\/acrabstracts.org\/abstract\/anti-il-17a-treatment-blocks-inflammation-destruction-and-new-bone-formation-in-experimental-spondyloarthritis-in-hla-b27-transgenic-rats\/. Accessed 10 Nov 2017.","DOI":"10.1136\/annrheumdis-2015-eular.3382"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib74","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib75","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/annrheumdis-2015-207544","article-title":"Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study","volume":"75","author":"Baraliakos","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib76","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2018.04.003_bib77","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218300581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218300581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T14:53:51Z","timestamp":1751554431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017218300581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0049017218300581"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.04.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics in SAPHO syndrome: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}